HBM-7022

N/A

Report date: 2026/03/19 17:01:20

Base Information

Drug NameHBM-7022
Drug Alias NameHBM-7022AZD-5863
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > T cell engagers
Mechanisms of ActionAnti-CD3Anti-CLDN18
TargetsT cell surface glycoprotein CD3Claudin-18 splice variant 2
Therapy Area/IndicationsEsophageal adenocarcinomaGastroesophageal Junction NeoplasmsPancreatic Neoplasms +[7] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesTaiwanNetherlands +[8] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesHarbour Biomed
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesAstrazeneca PlcAstraZeneca global R & D (China) Co Ltd
Inactive CompaniesHarbour Biomed
Active IndicationsEsophageal adenocarcinomaGastroesophageal Junction NeoplasmsPancreatic Neoplasms +[6] 
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A